- Current status of gastrointestinal tract cancer brain metastasis and the use of blood-based cancer biomarker biopsy.
- Assessment of Cell-Free microRNA by NGS Whole-Transcriptome Analysis in Cutaneous Melanoma Patients’ Blood.
- Regulation of MRE11A by UBQLN4 leads to cisplatin resistance in patients with esophageal squamous cell carcinoma.
- Genetic Variants in Immune Related Genes as Predictors of Responsiveness to BCG Immunotherapy in Metastatic Melanoma Patients.
- The melanoma brain metastatic microenvironment: aldolase C partakes in shaping the malignant phenotype of melanoma cells – a case of inter-tumor heterogeneity.
- Simultaneous Isolation of Circulating Nucleic Acids and EV-Associated Protein Biomarkers From Unprocessed Plasma Using an AC Electrokinetics-Based Platform.
- A Pilot Study Comparing the Efficacy of Lactate Dehydrogenase Levels Versus Circulating Cell-Free microRNAs in Monitoring Responses to Checkpoint Inhibitor Immunotherapy in Metastatic Melanoma Patients.
- Inter-Tumor Heterogeneity-Melanomas Respond Differently to GM-CSF-Mediated Activation.
- Integrated Assessment of Circulating Cell-Free MicroRNA Signatures in Plasma of Patients with Melanoma Brain Metastasis.
- Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors.
- Upregulation of cell surface GD3 ganglioside phenotype is associated with human melanoma brain metastasis.
- Downregulation of the Ubiquitin-E3 Ligase RNF123 Promotes Upregulation of the NF-?B1 Target SerpinE1 in Aggressive Glioblastoma Tumors.
- Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer.
- STAT3 Activation-Induced Fatty Acid Oxidation in CD8+ T Effector Cells Is Critical for Obesity-Promoted Breast Tumor Growth.
- Prospective Molecular Profiling of Circulating Tumor Cells from Patients with Melanoma Receiving Combinatorial Immunotherapy.
- Trends in Off-Label Drug Use in Ambulatory Settings: 2006-2015.
- The Immune Landscape of Cancer.
- Commonly integrated epigenetic modifications of differentially expressed genes lead to adaptive resistance in cancer.
- Regeneration Enhances Metastasis: A Novel Role for Neurovascular Signaling in Promoting Melanoma Brain Metastasis.
- B7H3 regulates differentiation and serves as a potential biomarker and theranostic target for human glioblastoma.
- Aneurysmal bone cyst treated with percutaneous doxycycline: is a single treatment sufficient?
- UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors.
- Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer.
- Detection of Minimal Residual Disease and Its Clinical Applications in Melanoma and Breast Cancer Patients.
- Epigenetic profiling for the molecular classification of metastatic brain tumors.
- Brain metastasis DNA methylomes, a novel resource for the identification of biological and clinical features.
- Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer.
- Predominance of triple wild-type and IGF2R mutations in mucosal melanomas.
- A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-ß Superfamily.
- Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial.
- Comprehensive Characterization of Cancer Driver Genes and Mutations.
- The Epigenomic Landscape of Pituitary Adenomas Reveals Specific Alterations and Differentiates Among Acromegaly, Cushing’s Disease and Endocrine-Inactive Subtypes.
- Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients.
- The metastatic microenvironment: Melanoma-microglia cross-talk promotes the malignant phenotype of melanoma cells.
- Epigenomic and Transcriptomic Characterization of Secondary Breast Cancers.
- KDM6B Counteracts EZH2-Mediated Suppression of IGFBP5 to Confer Resistance to PI3K/AKT Inhibitor Treatment in Breast Cancer.
- The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.
- Alternative splicing and cancer metastasis: prognostic and therapeutic applications.
- miR-29c plays a suppressive role in breast cancer by targeting the TIMP3/STAT1/FOXO1 pathway.
- Multiplex Gene Profiling of Cell-Free DNA in Patients With Metastatic Melanoma for Monitoring Disease.
- The Immune Landscape of Cancer.
- An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.
- A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples.
- Comprehensive Characterization of Cancer Driver Genes and Mutations.
- Pathogenic Germline Variants in 10,389 Adult Cancers.
- Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation.
- Oncogenic Signaling Pathways in The Cancer Genome Atlas.
- Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics.
- Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.
- Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas.
- lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer.
- A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.
- Genomic and Functional Approaches to Understanding Cancer Aneuploidy.
- Taylor AM, Shih J, Ha G, Gao GF, Zhang X, Berger AC, Schumacher SE, Wang C, Hu H, Liu J, Lazar AJ; Cancer Genome Atlas Research Network, Cherniack AD, Beroukhim R, Meyerson M.
- The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.
- Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context.
- Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types.
- Systematic Analysis of Splice-Site-Creating Mutations in Cancer.
- Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers.
- Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas.
- Driver Fusions and Their Implications in the Development and Treatment of Human Cancers.
- Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types.
- Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas.
- Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images.
- Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas.
- Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas.
- Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines.
- Distinct histone modifications denote early stress-induced drug tolerance in cancer.
- Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer.
- A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.
- Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines.
- ANGPTL4 promotes the progression of cutaneous melanoma to brain metastasis.
- Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas.
- Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence.
- P-REX1 amplification promotes progression of cutaneous melanoma via the PAK1/P38/MMP-2 pathway.
- Hypomethylation of CNTFRa is associated with proliferation and poor prognosis in lower grade gliomas.
- NADPH oxidase 5 (NOX5)-induced reactive oxygen signaling modulates normoxic HIF-1a and p27Kip1 expression in malignant melanoma and other human tumors.
- Emerging Utility of Urinary Cell-free Nucleic Acid Biomarkers for Prostate, Bladder, and Renal Cancers.
- The RhoJ-BAD signaling network: An Achilles’ heel for BRAF mutant melanomas.
- Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.
- MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in Metastatic Melanoma.
- Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.
- CCR4 is a determinant of melanoma brain metastasis.
- Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-?B Pathway in Melanoma.
- ATR Mutations Promote the Growth of Melanoma Tumors by Modulating the Immune Microenvironment.
- Genome-wide chromatin accessibility, DNA methylation and gene expression analysis of histone deacetylase inhibition in triple-negative breast cancer.
- The Impact of Smoking on Sentinel Node Metastasis of Primary Cutaneous Melanoma.
- LINE-1 hypomethylation status of circulating cell-free DNA in plasma as a biomarker for colorectal cancer.
- Circulating microRNA Biomarkers as Liquid Biopsy for Cancer Patients: Pros and Cons of Current Assays. J. Clin. Med. 2015, 4, 1890-1907.
- Liquid Biopsies for Assessing Metastatic Melanoma Progression.
- Donald L. Morton, MD…. A Legendary Surgical Oncologist and Consummate Investigator.
- Circulating Tumor DNA as a Cancer Biomarker: Fact or Fiction?
- B7-H4(B7x)-Mediated Cross-talk between Glioma-Initiating Cells and Macrophages via the IL6/JAK/STAT3 Pathway Lead to Poor Prognosis in Glioma Patients.
- Rapid Oligo-Galacturonide Induced Changes in Protein Phosphorylation in Arabidopsis.
- Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma.
- Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients.
- In Situ Sodium Bisulfite Modification of Genomic DNA from Microdissected Melanoma Paraffin-Embedded Archival Tissues.
- Epigenomic landscape of melanoma progression to brain metastasis: unexplored therapeutic alternatives.
- Regiodivergent Enantioselective ?-Additions of Oxazolones to 2,3-Butadienoates Catalyzed by Phosphines: Synthesis of a,a-Disubstituted a-Amino Acids and N,O-Acetal Derivatives.
- Corrigendum: IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.
- Circulating microRNA Biomarkers as Liquid Biopsy for Cancer Patients: Pros and Cons of Current Assays.
- IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.
- Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA.
- RASSF8 regulates progression of cutaneous melanoma through nuclear factor-?b.
- Highly enantioselective construction of tertiary thioethers and alcohols via phosphine-catalyzed asymmetric ?-addition reactions of 5H-thiazol-4-ones and 5H-oxazol-4-ones: scope and mechanistic understandings.
- Genomic Classification of Cutaneous Melanoma.
- Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications.
- The CASC15 Long Intergenic Noncoding RNA Locus Is Involved in Melanoma Progression and Phenotype Switching.
- Enantioselective synthesis of 3-fluoro-3-allyl-oxindoles via phosphine-catalyzed asymmetric ?-addition of 3-fluoro-oxindoles to 2,3-butadienoates.
- Lentivirus-induced ‘Smart’ dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma.
- Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer.
- A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients.
- Transcriptional repression of IFNß1 by ATF2 confers melanoma resistance to therapy.
- Vemurafenib resistance selects for highly malignant brain and lung-metastasizing melanoma cells.
- Multi-platform Genome-wide Analysis of Melanoma Progression to Brain Metastasis.
- MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A.
- Patient-specific driver gene prediction and risk assessment through integrated network analysis of cancer omics profiles.
- Genome-wide hypomethylation and specific tumor-related gene hypermethylation are associated with esophageal squamous cell carcinoma outcome.
- RASAL2 activates RAC1 to promote triple-negative breast cancer progression.
- CD8+ T-cell immunosurveillance constrains lymphoid premetastatic myeloid cell accumulation.
- Chromatin status of apoptosis genes correlates with sensitivity to chemo-, immune- and radiation therapy in colorectal cancer cell lines.
- Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas.
- Donald Lee Morton: in memoriam (1934-2014).
- Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome.
- DNA methylation of apoptosis genes in rectal cancer predicts patient survival and tumor recurrence.
- The metastatic microenvironment: Claudin-1 suppresses the malignant phenotype of melanoma brain metastasis.
- DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations.
- Molecular analysis of sentinel lymph nodes and search for molecular signatures of the metastatic potential of breast cancer.
- BAG3 protein expression in melanoma metastatic lymph nodes correlates with patients’ survival.
- Genome-wide characterization of circulating tumor cells identifies novel prognostic genomic alterations in systemic melanoma metastasis.
- Circulating tumor cells as prognostic biomarkers in cutaneous melanoma patients.
- Tumor necrosis factor-a and apoptosis induction in melanoma cells through histone modification by 3-deazaneplanocin A.
- Tanaka R, Donovan NC, Yu Q, Irie RF, Hoon DSB.
- Epigenetic status of LINE-1 predicts clinical outcome in early-stage rectal cancer.
- Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients.
- Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis.
- Epigenetic regulation of REG1A and chemosensitivity of cutaneous melanoma.
- Protein tyrosine phosphatase UBASH3B is overexpressed in triple-negative breast cancer and promotes invasion and metastasis.
- B cells promote tumor progression via STAT3 regulated-angiogenesis.
- Direct serum assay for microRNA in cancer patients.
- Assessment of DNA methylation status in early stages of breast cancer development.
- B7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma.
- BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition.
- Heterogeneous epigenetic regulation of TIMP3 in prostate cancer.
- Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial.
- DNA methylation index and methylation profile of invasive ductal breast tumors.
- Progression of cutaneous melanoma: implications for treatment.
- Lymphatics, lymph nodes and the immune system: barriers and gateways for cancer spread.
- A landscape of driver mutations in melanoma.
- Epigenetics of regional lymph node metastasis in solid tumors.
- Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer.
- S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites.
- Epigenetics of estrogen receptor-negative primary breast cancer.
- Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation.
- Hypomethylation of LINE-1 in primary tumor has poor prognosis in young breast cancer patients: a retrospective cohort study.
- The metastatic microenvironment: Brain-derived soluble factors alter the malignant phenotype of cutaneous and brain-metastasizing melanoma cells.
- AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome.
- Aberrant hypermethylation in primary tumours and sentinel lymph node metastases in paediatric patients with cutaneous melanoma.
- Epigenetic biomarkers in skin cancer.
- Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma.
- The metastatic microenvironment: brain-residing melanoma metastasis and dormant micrometastasis.
- Lymphovascular invasion of colorectal cancer is correlated to SPARC expression in the tumor stromal microenvironment.
- Cell-free nucleic acids as biomarkers in cancer patients.
- Prognostic molecular biomarkers for cutaneous malignant melanoma.
- LINE-1 hypomethylation during primary colon cancer progression.
- Molecular mechanisms of metastasis.
- Primary tumor classification according to methylation pattern is prognostic in patients with early stage ER-negative breast cancer.
- A novel automated assay for the rapid identification of metastatic breast carcinoma in sentinel lymph nodes.
- Kinesin 18A expression: clinical relevance to colorectal cancer progression.
- Molecular upstaging based on paraffin-embedded sentinel lymph nodes: ten-year follow-up confirms prognostic utility in melanoma patients.
- B7-h3 ligand expression by primary breast cancer and associated with regional nodal metastasis.
- Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma.
- Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer.
- Development of sporadic microsatellite instability in colorectal tumors involves hypermethylation at methylated-in-tumor loci in adenoma.
- Identification of a quantitative MINT locus methylation profile predicting local regional recurrence of rectal cancer.
- FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer.
- Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma.
- Chemokine-chemokine receptor axes in melanoma brain metastasis.
- High molecular weight-melanoma-associated antigen as a biomarker of desmoplastic melanoma.
- Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment.
- Aberrant fatty acid-binding protein-7 gene expression in cutaneous malignant melanoma.
- Functional RET G691S polymorphism in cutaneous malignant melanoma.
- Analysis of loss of heterozygosity in circulating DNA.
- Regulation of RUNX3 tumor suppressor gene expression in cutaneous melanoma.
- mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads.
- CpG island methylator phenotype predicts progression of malignant melanoma.
- LC/MS-based quantitative proteomic analysis of paraffin-embedded archival melanomas reveals potential proteomic biomarkers associated with metastasis.
- Multimarker circulating DNA assay for assessing blood of prostate cancer patients.
- Prognostic relevance of occult nodal micrometastases and circulating tumor cells in colorectal cancer in a prospective multicenter trial.
- Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors.
- Analysis of methylated circulating DNA in cancer patients’ blood.
- Quantification of LINE1 in circulating DNA as a molecular biomarker of breast cancer.
- Multidetector computed tomography pulmonary angiography: does arm position affect pulmonary artery enhancement?
|
- False negative sentinel lymph node biopsies in melanoma may result from deficiencies in nuclear medicine, surgery, or pathology.
- Human high molecular weight-melanoma-associated antigen: utility for detection of metastatic melanoma in sentinel lymph nodes.
- Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors.
- Quantitative analysis of methylation of genomic loci in early-stage rectal cancer predicts distant recurrence.
- Sequestosome 1 (SQSTM1) mutations in Paget’s disease of bone from the United States.
- Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine.
- The role of estrogen receptor in melanoma.
- Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer.
- Effects of chemokines on tumor metastasis.
- Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial.
- Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes.
- Assessment of methylation events during colorectal tumor progression by absolute quantitative analysis of methylated alleles.
- Sentinel lymph node molecular ultrastaging in patients with melanoma: a systematic review and meta-analysis of prognosis.
- Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy.
- Immunity against breast cancer by TERT DNA vaccine primed with chemokine CCL21.
- Hypermethylation of adenosine triphosphate-binding cassette transporter genes in primary hyperparathyroidism and its effect on sestamibi imaging.
- Proteomic profiling of primary breast cancer predicts axillary lymph node metastasis.
- Higher amount of free circulating DNA in serum than in plasma is not mainly caused by contaminated extraneous DNA during separation.
- Epigenetic analysis of body fluids and tumor tissues: application of a comprehensive molecular assessment for early-stage breast cancer patients.
- Comparative analysis of mesenteric and peripheral blood circulating tumor DNA in colorectal cancer patients.
- Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma.
- Prediction of breast tumor progression by integrity of free circulating DNA in serum.
- Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma.
- The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis.
- Estrogen receptor-alpha methylation predicts melanoma progression.
- Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome.
- Prospective multicenter trial of staging adequacy in colon cancer: preliminary results.
- Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients.
- Molecular mechanisms of metastasis.
- Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats.
- Methylation of p16 and Ras association domain family protein 1a during colorectal malignant transformation.
- Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins.
- Molecular upstaging of sentinel lymph nodes in melanoma: where are we now?
- A new melanoma antigen fatty acid-binding protein 7, involved in proliferation and invasion, is a potential target for immunotherapy and molecular target therapy.
- Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients.
- Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy.
- The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling.
- The clinical significance of MAGEA3 expression in pancreatic cancer.
- X-Linked inhibitor of apoptosis protein expression level in colorectal cancer is regulated by hepatocyte growth factor/C-met pathway via Akt signaling.
- Are circulating tumor cells an independent prognostic factor in patients with high-risk melanoma?
- Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial.
- Molecular diagnosis of micrometastasis in the sentinel lymph node.
- Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant.
- Molecular markers in malignant cutaneous melanoma: gift horse or one-trick pony?
- DNA vaccines for cancer treatment.
- Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine.
- Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer.
- Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival.
- Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients.
- Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis.
- Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells.
- Synthesis of universal unmethylated control DNA by nested whole genome amplification with phi29 DNA polymerase.
- Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis.
- Allelic imbalance of APAF-1 locus at 12q23 is related to progression of colorectal carcinoma.
- Circulating nucleic acids in plasma and serum: past, present and future.
- Detection of differentially expressed proteins in early-stage melanoma patients using SELDI-TOF mass spectrometry.
- Detection of mitochondrial DNA alterations in plasma of malignant melanoma patients.
- Quantification of circulating DNA in the plasma and serum of cancer patients.
- Circulating nucleic acids and proteomics of plasma/serum: clinical utility.
- Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients.
- Peptide nucleic acid clamp PCR: a novel K-ras mutation detection assay for colorectal cancer micrometastases in lymph nodes.
- Allelic imbalance on 12q22-23 in serum circulating DNA of melanoma patients predicts disease outcome.
- Frequent LOH at chromosome 12q22-23 and Apaf-1 inactivation in glioblastoma.
- CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells.
- Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients.
- Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma.
- Clinicopathological utility of molecular staging for melanoma patients undergoing sentinel lymphadenectomy.
- Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas.
- Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma.
- Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases.
- Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes.
- Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine.
- Detection of tumor-specific genetic alterations in bone marrow from early-stage breast cancer patients.
- c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases.
- Stanniocalcin-1: a novel molecular blood and bone marrow marker for human breast cancer.
- Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
- A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma.
- Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas.
- The use of molecular profiling of early colorectal cancer to predict micrometastases.
- Assessment of genetic heterogeneity in tumors using laser capture microdissection.
- Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes.
- Molecular lymphatic mapping of the sentinel lymph node.
- Ultrastaging of early colon cancer using lymphatic mapping and molecular analysis.
- Overexpression of beta 1,4N-acetylgalactosaminyl- transferase mRNA as a molecular marker for various types of cancers.
- Induction of a systemic immune response by a polyvalent melanoma-associated antigen DNA vaccine for prevention and treatment of malignant melanoma.
- Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease.
- Detection of MAGE-A3 in breast cancer patients’ sentinel lymph nodes.
- Microsatellite alterations detected in the serum of early stage breast cancer patients.
- Molecular detection of metastatic melanoma cells in cerebrospinal fluid in melanoma patients.
- Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow.
- Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients.
- Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles.
- Pathologic examination of sentinel lymph node for breast carcinoma.
- Functional interleukin-4 receptor and interleukin-2 receptor common gamma chain in human gastric carcinoma: a possible mechanism for cytokine-based therapy.
- Molecular clonality of in-transit melanoma metastasis.
- Molecular strategy for detecting metastatic cancers with use of multiple tumor-specific MAGE-A genes.
- Molecular staging of early colon cancer on the basis of sentinel node analysis: a multicenter phase II trial.
- The clinical utility of multimarker RT-PCR in the detection of occult metastasis in patients with melanoma.
- Induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon-gamma retroviral vector in melanoma patients.
- Microsatellite analysis of melanoma lesions using (CA)13 oligonucleotides as an internal probe.
- Clinical significance of circulating DNA microsatellite markers in plasma of melanoma patients.
- Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence.
- PTEN / MMAC1 mutation and frequent loss of heterozygosity identified in chromosome 10q in a subset of hepatocellular carcinomas.
- Molecular detection of metastatic pancreatic carcinoma cells using a multimarker reverse transcriptase-polymerase chain reaction assay.
- Functional interleukin 4 receptor and interleukin 2 receptor common gamma-chain on human non-small cell lung cancers: novel targets for immune therapy.
- RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization.
- Protective immunization against melanoma by gp100 DNA-HVJ-liposome vaccine.
- Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients.
- Cytotoxic T lymphocytes that recognize decameric peptide sequences of retinoblastoma binding protein 1 (RBP-1) associated with human breast cancer.
- Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients.
- Detection of carcinoembryonic antigen messenger RNA in lymph nodes from patients with colorectal cancer.
- Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy.
- Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple-marker RT-PCR.
- Antibody responses to melanoma/melanocyte autoantigens in melanoma patients.
- Augmentation of IgM antibody to gp43 tumor-associated antigen peptide by melanoma cell vaccine.
- Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients.
- Cellular immuno-PCR. Detection of a carbohydrate tumor marker.
- Detection of tyrosinase mRNA in melanoma by reverse transcription-PCR and electrochemiluminescence.
- Human IgM antibodies to tumor-associated gangliosides share VHIII (V3-23) and VKIV family subgroups.
- Assessment of messenger RNA of beta 1–>4-N-acetylgalactosaminyl-transferase as a molecular marker for metastatic melanoma.
- Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients?
- Induction of antibody response to human tumor antigens by gene therapy using a fusigenic viral liposome vaccine.
- Prognostic implications of p53 overexpression in cutaneous melanoma from sun-exposed and nonexposed sites.
- 707-AP peptide recognized by human antibody induces human leukocyte antigen A2-restricted cytotoxic T lymphocyte killing of melanoma.
- Recognition of gp43 tumor-associated antigen peptide by both HLA-A2 restricted CTL lines and antibodies from melanoma patients.
- Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas.
- Melanoma-associated antigens as messenger RNA detection markers for melanoma.
- Current status of human melanoma vaccines: can they control malignant melanoma?
- Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma.
- Detection of metastatic breast cancer by beta-hCG polymerase chain reaction.
- Interleukin 4 inhibits hepatocyte growth factor-induced invasion and migration of colon carcinomas.
- Detection of beta-human chorionic gonadotropin mRNA as a marker for cutaneous malignant melanoma.
- The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction.
- Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay.
- Cytotoxic T cell recognition of a human melanoma derived peptide with a carboxyl-terminal alanine-proline sequence.
- Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen.
- A decapeptide (Gln-Asp-Leu-Thr-Met-Lys-Tyr-Gln-Ile-Phe) from human melanoma is recognized by CTL in melanoma patients.
- Characterization and augmentation of CD4+ cytotoxic T cell lines against melanoma.
- Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response.
- Interleukin 4 regulates G1 cell cycle progression in gastric carcinoma cells.
- Aberrant expression of gangliosides in human renal cell carcinomas.
- Interleukin-4 plus tumor necrosis factor alpha augments the antigenicity of melanoma cells.
- Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers.
- Augmentation of T-cell response with a melanoma cell vaccine expressing specific HLA-A antigens.
- Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma.
- A preclinical model to assess the antigenicity of an HLA-A2 melanoma cell vaccine.
- Transfection of interleukin 2 gene into human melanoma cells augments cellular immune response.
- Growth inhibition and modulation of cell markers of melanoma by S-allyl cysteine.
- Interleukin 4 receptor expression and growth inhibition of gastric carcinoma cells by interleukin 4.
- Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.
- Ganglioside GM2 levels in human melanoma cells: inverse correlation with lysosomal beta-hexosaminidase A activity.
- Cite Share
- Induction of CD4+ cytotoxic T cells by sensitization with allogeneic melanomas bearing shared or cross-reactive HLA-A.
- Modulation of histamine type II receptors on CD8+ T cells by interleukin-2 and cimetidine.
- Cytotoxic T cell lines recognize autologous and allogeneic melanomas with shared or cross-reactive HLA-A.
- Interleukin 4 alone and with gamma-interferon or alpha-tumor necrosis factor inhibits cell growth and modulates cell surface antigens on human renal cell carcinomas.
- Modulation of human melanoma cells by interleukin-4 and in combination with gamma-interferon or alpha-tumor necrosis factor.
- Production of tumor necrosis factor alpha and interferon gamma in interleukin-2-treated melanoma patients: correlation with clinical toxicity.
- Anti-idiotype monoclonal antibody carrying the internal image of ganglioside GM3.
- Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide.
- Generation of lymphokine-activated killer cell activity by low-dose recombinant interleukin-2 and tumor cells.
- Immunosuppression by melanoma cells as a factor in the generation of metastatic disease.
- Ganglioside GM2 expression on human melanoma cells correlates with sensitivity to lymphokine-activated killer cells.
- Modulation of human macrophage functions by gangliosides.
- S-100 protein stimulates cellular proliferation.
- Variations in lymphokine generation by individual lymph nodes draining human malignant tumors.
- Active specific immunotherapy in malignant melanoma.
- A comparison of solutions for lung preservation using pulmonary alveolar type II cell viability.
- Gangliosides from human melanoma immunomodulate response of T cells to interleukin-2.
- Immunobiology of human cutaneous melanoma.
- Isolation of lymphocytes from clotted blood.
- Cyclophosphamide-induced alterations in human monocyte functions.
- The regulatory effect of adherent cells on lymphokine activated killer cells.
- Ganglioside GM2 on the K562 cell line is recognized as a target structure by human natural killer cells.
- Reactivity of neoplastic cells of hairy cell leukemia with antisera to S-100 protein.
- Variations in functional immunocompetence of individual tumor-draining lymph nodes in humans.
- Suppressor cell activity in melanoma-draining lymph nodes.
- Zoned immune suppression of lymph nodes draining malignant melanoma: histologic and immunohistologic studies.
- A 6-thioguanine-resistant variant of the rat mammary adenocarcinoma 13762 that is more immunogenic.
- Inhibition of lymphocyte motility by interleukin 2.
- Analysis of mammary tumour cell metastasis and release of bound n-acetylneuraminic acid.
- Chemoimmunotherapeutic effect of cyclophosphamide on the highly metastatic MAT 13762 tumor.
- Increased metastatic ability and bone formation of a mammary adenocarcinoma in vivo after in vitro passaging.
- Circulating immune complexes in rats bearing 6-thioguanine-resistant variants of the 13762 mammary adenocarcinoma.
- Circulating immune complexes and immunoglobulin M-class rheumatoid factor in rats bearing mammary adenocarcinomas which vary in ability to metastasize.
- A 6-thioguanine-resistant variant of the 13762 cell line which is no longer tumorigenic or metastatic.
|
